MK-3120 for neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 10 Feb 2025: Trial registered, NCT06818643
  2. 25 Mar 2025: Trial started, NCT06818643

The trials

NCT06818643: A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

State
Under way
Phase
Phase 1 and Phase 2
People
270 planned
Started
25 Mar 2025
Primary completion
8 Feb 2028
Arms
Arm 1 Dose level 1, Arm 2 Dose level 2
Results
None posted
  1. 10 Feb 2025: Trial registered
  2. 25 Mar 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.